Ph 1b in PD-apathy starts in H2'25 Safety and early efficacy the main goals Comes with USD 4.5m cash injection from MSRD
ANNONS
Ph 1b in PD-apathy with MSRD
Today IRLAB Therapeutics announced the initiation of a Ph 1b study with the apathy candidate IRL757. The first patient in (FPI) is planned for H2'25 and IRLAB's collaboration partner MSRD will finance the startup cost through an initial payment of USD 4.5m to be booked still in Q1. The decision builds on the collaboration agreement signed with MSRD in May'24.
